AHA: American Heart Association
Conference Coverage
Uptake of high-sensitivity troponin assays lags in U.S. hospitals
A national analysis found that only one-third of hospitals are utilizing the assays, despite the first test being approved in 2017.
Conference Coverage
Marital stress tied to worse outcome in young MI patients
For younger patients recovering from myocardial infarction, managing personal stress may be as important as addressing other clinical risk factors...
Conference Coverage
AHA 2022 to recapture in-person vibe but preserve global reach
Planners see the meeting’s Chicago return as a hybrid after 2 years relegated to cyberspace as a chance for first impressions on some just...
Conference Coverage
New AKI risk score for PCI patients passes validation
Conference Coverage
New CETP inhibitor impresses in LDL lowering
A new lipid-lowering agent, obicetrapib, in a class that had been written off by many, is being developed by a group of academic experts, with new...
Conference Coverage
SGLT2 inhibitor use tied to fewer atrial arrhythmias
Conference Coverage
Could an oral PCSK9 inhibitor be on the horizon?
What if the cholesterol-crushing efficacy of current PCSK9 inhibitors came in a pill instead of a syringe? That’s one possibility for a Merck...
Conference Coverage
Penicillin slows latent rheumatic heart disease progression
Secondary antibiotic prophylaxis can improve outcomes for children with echo-detected rheumatic heart disease, a randomized trial in Uganda shows...
Conference Coverage
Firefighters’ blood pressure surges when they are called to action
The finding may help explain why 50% of firefighter deaths in the line of duty are from cardiovascular disease, and suggests that physicians and...
Conference Coverage
Empagliflozin a winner in challenging arena of stabilized acute HF
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of...
Conference Coverage
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
Conference Coverage
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a...
Conference Coverage
ASCEND: Aspirin shows hint of dementia protection in T2D
Conference Coverage
High-dose fish oil: ‘Intriguing’ results in COVID-19
Conference Coverage
DREAM-HF: Negative stem cell trial in heart failure may still offer promise
Despite zero evidence of benefit on the primary endpoint, stem cell transplant is still promising in heart failure.